STOCK TITAN

Synaptogenix Inc - SNPX STOCK NEWS

Welcome to our dedicated news page for Synaptogenix (Ticker: SNPX), a resource for investors and traders seeking the latest updates and insights on Synaptogenix.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Synaptogenix's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Synaptogenix's position in the market.

Rhea-AI Summary
Synaptogenix, Inc. (SNPX) announces a reverse stock split at a ratio of 1:25 to increase per-share trading price and comply with Nasdaq listing requirements. The split will be effective on April 4, 2024, with trading starting on a split-adjusted basis on April 5, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.17%
Tags
-
Rhea-AI Summary
Synaptogenix, Inc. (Nasdaq: SNPX) announced that its President and Chief Scientific Officer, Dr. Daniel L. Alkon, was honored for his presentation on the benefits of Bryostatin-1 in severe Alzheimer's disease patients at the IABS Forum-2023. The clinical data from the Phase 2 trial of Bryostatin-1 showed statistically significant benefits for severe AD patients, with no significant cognitive decline observed throughout the 10-month study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.45%
Tags
none
-
Rhea-AI Summary
Synaptogenix, Inc. (Nasdaq: SNPX) to feature lead therapeutic's statistically significant benefits for severe Alzheimer's disease patients at IABS Forum-2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.27%
Tags
none
Rhea-AI Summary
Synaptogenix, Inc. acquires a 25% stake in Cannasoul Analytics for up to $4 million to support R&D for cannabinoid- and psilocybin mushroom-based therapeutics. The partnership aims to drive the development and commercialization of Cannasoul Analytics' intellectual property and technologies licensed from The Technion - Israel Institute of Technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.7%
Tags
-
Rhea-AI Summary
Synaptogenix announces statistically significant benefits of Bryostatin-1 in severe Alzheimer's disease patients, with no significant cognitive decline in the 10-month trial compared to placebo patients. The data suggests a long-lasting positive change in treated patients' brains. The company believes Bryostatin-1 could provide a complementary treatment option for advanced-stage Alzheimer's patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.56%
Tags
-
Rhea-AI Summary
Synaptogenix, Inc. (SNPX) Announces Positive Findings in ALS Study
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.17%
Tags
none
Rhea-AI Summary
Synaptogenix announces collaboration with Cleveland Clinic for phase 1 trial of Bryostatin-1 in MS. The trial will evaluate the drug's potential neuro-restorative mechanism(s) of action for improving synaptic health and cognitive function in MS patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.19%
Tags
-
Rhea-AI Summary
Synaptogenix, Inc. announced that the abstract featuring secondary endpoint data of its Phase 2 Bryostatin-1 trial was accepted for presentation at the 11th International Brain Research Organization World Congress of Neuroscience. The trial showed significant benefits for patients in the Severe Cohort with advanced Alzheimer's disease, while the Moderate Cohort showed no significant benefit. The company believes that Bryostatin-1 can prevent cognitive decline in advanced AD patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.79%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.03%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-74.63%
Tags
Synaptogenix Inc

Nasdaq:SNPX

SNPX Rankings

SNPX Stock Data

5.09M
1.06M
2.44%
3.91%
1.1%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
New York

About SNPX

synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases.